|Day's Range||28.75 - 28.75|
Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
During Friday night's Mad Money program host Jim Cramer mentioned that there are some companies with confusing outlooks such as AbbVie Inc. , which acquired Allergan. Allergan's focus has been with Botox and cosmetic surgeries, which are also on hold. In the daily bar chart of ABBV, below, we can see that prices retreated to the August lows before rebounding in recent sessions.
Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
AbbVie Inc. (NYSE: ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes of certain series issued by Allergan Finance, LLC ("Allergan Finance"), Allergan, Inc. ("Allergan Inc"), Allergan Sales, LLC ("Allergan Sales") and Allergan Funding SCS ("Allergan Funding" and, together with Allergan Finance, Allergan Inc and Allergan Sales, "Allergan") (the "Allergan Notes") for new notes to be issued by AbbVie (the "AbbVie Notes") and the related consent solicitations (each, a "Consent Solicitation" and, collectively, the "Consent Solicitations") being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures (each, an "Allergan Indenture") governing the Allergan Notes. AbbVie hereby extends such expiration date from 5:00 p.m., New York City time, on April 10, 2020 to 5:00 p.m., New York City time, on April 24, 2020 (as the same may be further extended, the "Expiration Date").
At least three clinical trials for hydroxychloroquine are trying to establish whether the decades-old malaria medication can prevent COVID-19 infections in frontline health-care workers as hospitals across the country scramble to secure enough gowns and masks for their employees.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Jim Cramer said on CNBC's "Mad Money Lightning Round" AbbVie Inc (NYSE: ABBV) traded lower on COVID-19, but he likes its dividend yield and it remains a great stock. It's a big position for his charitable trust fund.Clarivate Analytics PLC (NYSE: CCC) is a research company, but Cramer hadn't thought of it as a COVID-19 play. He needs to do more research to see if it is worth buying on that.Cramer is a buyer of Domino's Pizza, Inc. (NYSE: DPZ). He believes the company has a great delivery, which makes it a terrific investment.There is too much supply in the oil and gas pipelines sector, thinks Cramer. He doesn't like pipelines and natural gas anymore and he doesn't like Kinder Morgan Inc (NYSE: KMI).See more from Benzinga * RNC Genter Capital CEO Likes Tech, Health Care, Financials In Volatile Market(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2020 financial results on Friday, May 1, 2020, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.